Insulet Corporation (PODD) delivered the kind of quarter that makes investors smile on Wednesday, posting earnings that sailed past Wall Street's estimates while laying out an ambitious growth roadmap for the year ahead. The automated insulin delivery technology maker's stock jumped 9% as traders digested the strong performance and management's confidence in buying back a hefty chunk of shares.
The numbers tell a compelling story. Fourth-quarter adjusted earnings hit $1.55 per share, comfortably ahead of the $1.45 consensus estimate. Revenue reached $783.8 million, marking a 31.2% increase year-over-year (29% in constant currency), which not only beat analyst expectations of $768.69 million but also exceeded the high end of the company's own guidance range of 25% to 28% constant currency growth.
The real star of the show was Omnipod revenue, which came in at $781.8 million—a 33.5% jump, or 31.3% in constant currency terms. Drug delivery revenue contributed another $2.0 million to the total.
Profitability metrics showed steady improvement across the board. Gross margin expanded to 72.5%, up 40 basis points from the prior year. Operating income reached $146.3 million, representing 18.7% of revenue and climbing 40 basis points year-over-year. Adjusted operating income matched that at $146.2 million, with margins up 30 basis points.
"We ended the year with another excellent quarter, demonstrating the power of our business model, the strength of our technology, and the disciplined execution of our team," said Ashley McEvoy, President and CEO.
Capital Allocation Gets Aggressive
Perhaps the most attention-grabbing announcement was Insulet's board approving a $350 million increase to the company's share repurchase authorization. Management isn't messing around with timing either—the company plans to deploy approximately $300 million toward buybacks in the first quarter of 2026 alone, funding the purchases with existing cash.
The expanded authorization reflects what management called the company's strong balance sheet, financial flexibility, and disciplined approach to capital allocation. Translation: business is good enough that they're comfortable returning serious cash to shareholders.
Looking Ahead to 2026
"As we move into 2026, we are confident in our ability to grow the global AID market, expand adoption across type 1 and type 2 diabetes, and deliver on the strategic and financial commitments we have laid out," McEvoy commented.
The fiscal 2026 outlook matched that confidence. Insulet forecasts sales between $3.250 billion and $3.304 billion (versus consensus of $3.25 billion), representing year-over-year growth of 20%-22%. Within that, total Omnipod Products growth is expected to come in between 21%-23%.
The margin expansion story continues too. Adjusted operating margin should widen by approximately 100 basis points, while adjusted earnings per share are projected to grow by over 25%—significantly outpacing revenue growth.
For the first quarter specifically, the company expects sales between $705.5 million and $716.94 million, compared to analyst estimates of $713.41 million.
Stock Performance: Insulet shares climbed 9.00% to $268.52 on Wednesday, trading 16.7% above the stock's 52-week low.
